Enliven Therapeutics (ELVN) Preferred Shares (2022)
Enliven Therapeutics has reported Preferred Shares over the past 1 years, most recently at $149.7 million for Q4 2022.
- Quarterly results put Preferred Shares at $149.7 million for Q4 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was $149.7 million (changed N/A YoY), and the annual figure for FY2022 was $149.7 million, changed.
- Preferred Shares reached $149.7 million in Q4 2022 per ELVN's latest filing.
- Across five years, Preferred Shares topped out at $149.7 million in Q4 2022 and bottomed at $149.7 million in Q4 2022.